All In Biotech

Free tool

FAERS Monitor: Piasky

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761388 or its brand name (Piasky, Crovalimab-Akkz). Reports on generic versions are filed under their own applications.

Reports

121

Serious

115

95% of reports

Hospitalization

69

Death reported

12

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pyrexia21
  • type iii immune complex mediated reaction21
  • anaemia20
  • off label use15
  • haemolysis14
  • infection11
  • breakthrough haemolysis10
  • pneumonia10
  • hepatic function abnormal8
  • covid-197
  • haemoglobin decreased7
  • sepsis7
  • urinary tract infection7
  • arthralgia6
  • drug ineffective6

Reports by year received

View as table
YearReports
202412
202554
202655

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,038 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
type iii immune complex mediated reactionSignal216791.84562.3130,775
breakthrough haemolysisSignal104473.02450.239,339
haemolysisSignal14315.7192.84,077
hepatic function abnormalSignal837.319.1248
anaemiaSignal2018.212.2311
infectionSignal1113.27.5113
haemoglobin decreasedSignal711.95.859
sepsisSignal710.95.354
pyrexiaSignal2110.67.2175
urinary tract infectionSignal77.13.531
covid-19Signal76.93.430
pneumoniaSignal105.43.032
off label useSignal153.01.919
arthralgiaSignal62.51.14
drug ineffective60.80.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.